Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Authors
Mease PJ, Orbai AM, FitzGerald O, Bedaiwi M, Dona L Fleishaker , Mundayat R, Young P, Helliwell PS
Abstract
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and patient-reported outcomes (PROs), in patients with PsA.
